LeadingBiotech, an exclusive event series bringing together senior-level biopharma leaders through off-the-record collaboration and dialogue, announces its Boston BD conference to be held on September 10, 2019, at the Westin Boston Waterfront Hotel.
BOSTON (PRWEB) JULY 25, 2019
LeadingBiotech, an exclusive event series bringing together senior-level biopharma leaders through off-the-record collaboration and dialogue, today announces its Boston BD conference to be held on September 10, 2019, at the Westin Boston Waterfront Hotel. As part of Biotech Week Boston, the event provides an opportunity for attendees to leverage insight from real-life business development experiences, network with biopharma executives and share insights on the business challenges and opportunities impacting the industry.
“It’s a great conference to meet like-minded people working in the same space. Excellent for networking and thought-provoking discussion,” commented Lesley Solomon, SVP Innovation, Chief Innovation Officer, Dana-Farber Cancer Institute, and a speaker at this year’s event.
Key topics at this year’s conference include Improving Patients Lives & Re-Defining Value, Pioneering New Business Models for Creative Deal Structures, and a fireside chat on True Collaborations Between Companies.
Keynote speakers at the conference include:
- Mary Lynne Hedley, Ph.D., President and COO, TESARO
- Jeb Keiper, M.S., M.B.A., CEO, Nimbus Therapeutics
- David K. Lee, CEO, Servier Pharmaceuticals
- Lonnie Moulder, Founding General Partner, Tellus BioVentures and Venture Advisor, NEA
- Praveen Tipirneni, President and CEO, Morphic Therapeutics
- James Tobin, Ph.D., Vice President, Cardiovascular and Metabolic Scientific Innovation, Johnson & Johnson Innovation
Other new speakers include
- Kerrie Brady, BPharm, M.S., M.B.A., CBO & EVP, Corporate Strategy, Centrexion Therapeutics
- Michelle Doig, Partner, Omega Funds
- Elcin Ergun, M.B.A., EVP, President New Business, EMD Serono
- Bill Geary, Co-Founder & General Partner, Flare Capital Partners
- Sophie Kornowski, Senior Partner, Gurnet Point Capital
- Reenie McCarthy, CEO, Stealth BioTherapeutics
- Ronald Renaud, CEO, Translate Bio
- Lesley Solomon, SVP Innovation, Chief Innovation Officer, Dana-Farber Cancer Institute
- Alex Waldron, Chief Strategy Officer, Pear Therapeutics
Save $400 with the early bird rate if you register before August 1. Reserve your spot now.
Nominate a Rising Star in the Biopharma Community:
New this year, LeadingBiotech is accepting nominations for a Rising Star, an experienced executive who is an up-and-coming mover and shaker in the biopharma community. Nominations are being accepted through August 15, 2019. The elected Rising Star will receive a complimentary pass to Boston BD. Nominate someone for this recognition here.
About LeadingBiotech
Formerly known as Boston Biotech Conferences, LeadingBiotech is an event series that brings biopharma CEOs and leaders together through intimate, off-the-record collaboration. We are working hard to create more valuable experiences to re-energize collaboration and infuse fresh ideas to better shape the future of biotech. For more information, please visit: https://leadingbiotech.com/.
It’s a great conference to meet like-minded people working in the same space. Excellent for networking and thought-provoking discussion.” – Lesley Solomon, SVP Innovation, Chief Innovation Officer, Dana-Farber Cancer Institute.
